The Clinical Trials Transformation Initiative (CTTI) has unveiled new recommendations for the use of real-world data (RWD) sources to improve the quality and efficiency of clinical trials.
The release of new recommendations, resources, and case studies for using electronic medical records (EHRs) and claims data is aimed at planning trial eligibility criteria and recruiting potential research participants.
Go deeper with GlobalData
CTTI’s latest work bridged a key gap across the clinical trials ecosystem. The potential benefits of RWD have been acknowledged in the ecosystem.
CTTI executive director Pamela Tenaerts said: “We are excited to unveil this comprehensive set of work, which enables the use of RWE to plan for appropriate eligibility criteria and optimal recruitment in clinical trials.
“These recommendations add to CTTI’s growing portfolio of work focused on improving clinical quality and, when appropriate, embracing novel approaches for better trial design and execution.”
The RWD and real-world evidence (RWE) tools are collected through the routine delivery of health care for improving the clinical trial quality.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe recommendations and resources, along with three case studies, were released by CTTI after conducting research in collaboration with stakeholders across the clinical trials ecosystem.
Elucidating the process of integrating RWD into trial design, the case studies offer a dive into the specific challenges each sponsor faces, and the way they can be addressed.
CTTI will also co-lead a proof-of-concept study for evaluating the feasibility of using the Food and Drug Administration (FDA) Sentinel System infrastructure to carry out randomised clinical trials.
It will also focus on recommendations on how to assess and design registries so that the data can meet expectations for the review of new products by the FDA.
